Professor Andrew Mearns Spragg is a marine biotechnology entrepreneur with over 10 years commercial experience in developing and growing a successful venture backed business. He grew his first company, Aquapharm whilst holding a Royal Society of Edinburgh (RSE) Enterprise Fellowship in biotechnology and grew this to a company of >20FTEs focusedon the development of novel targeted treatments for cancer and drug resistant bacteria (antibiotics) from chemical scaffolds derived from marine microorganisms, an untapped source of natural product chemistry. Since 2005, Prof Spragg has successfully raised over £10M in equity finance and secured >£1.5M competitive grant funding from EU and UK sources. Prof Spragg brings an extensive international contact network across the finance, pharmaceutical, consumer care & IB sectors.